Pea3 expression promotes the invasive and metastatic potential of colorectal carcinoma

World Journal of Gastroenterology

Volumn 20, Issue 46, 2014, Pages 17376-17387

  Mesci, Aruz ^a,b   Taeb, Samira ^b   Huang, Xiaoyong ^b   Jairath, Rishi ^b   Sivaloganathan, Darshan ^b   Liu, Stanley K ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b Sunnybrook Health Sciences Centre   (Canada)

Author keywords

Colorectal cancer; Epithelial mesenchymal transition; Liver metastasis; Pea3

Indexed keywords

MATRIX METALLOPROTEINASE; MESSENGER RNA; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR PEA3; E1A PROTEIN; ETV4 PROTEIN, HUMAN; ONCOPROTEIN;

ANIMAL EXPERIMENT; ANOIKIS; ARTICLE; CANCER CELL LINE; CANCER PROGNOSIS; CELL INVASION; CELL LYSATE; CELL PROLIFERATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FILTERS AND MEMBRANES; FLUOROMETRY; GENE; GENE EXPRESSION; HCT116 CELL LINE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER METASTASIS; METASTASIS POTENTIAL; MOUSE; MTS ASSAY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SPLEEN; TUMOR GROWTH; TUMOR INVASION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA; CELL MOTION; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; LIVER NEOPLASMS; METABOLISM; NUDE MOUSE; PATHOLOGY; SECONDARY; SIGNAL TRANSDUCTION; TIME; TUMOR VOLUME;

ADENOVIRUS E1A PROTEINS; ANIMALS; ANOIKIS; CARCINOMA; CELL MOVEMENT; CELL PROLIFERATION; COLORECTAL NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HEK293 CELLS; HUMANS; LIVER NEOPLASMS; MATRIX METALLOPROTEINASES; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TUMOR BURDEN;

EID: 84918531274     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i46.17376     Document Type: Article

References (43)

1. Arends MJ. Pathways of colorectal carcinogenesis. Appl Immunohistochem Mol Morphol 2013; 21: 97-102 [PMID: 23417071 DOI: 10.1097/PAI.0b013e31827ea79e]
2. Heinemann V, Douillard JY, Ducreux M, Peeters M. Targeted therapy in metastatic colorectal cancer - an example of personalised medicine in action. Cancer Treat Rev 2013; 39: 592-601 [PMID: 23375249 DOI: 10.1016/j.ctrv.2012.12.011]
3. Shindoh M, Higashino F, Kohgo T. E1AF, an ets-oncogene family transcription factor. Cancer Lett 2004; 216: 1-8 [PMID: 15500943 DOI: 10.1016/j.canlet.2004.07.020]
4. Oh S, Shin S, Janknecht R. ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors. Biochim Biophys Acta 2012; 1826: 1-12 [PMID: 22425584 DOI: 10.1016/j.bbcan.2012.02.002]
5. Higashino F, Yoshida K, Fujinaga Y, Kamio K, Fujinaga K. Isolation of a cDNA encoding the adenovirus E1A enhancer binding protein: a new human member of the ets oncogene family. Nucleic Acids Res 1993; 21: 547-553 [PMID: 8441666]
6. Chotteau-Lelièvre A, Desbiens X, Pelczar H, Defossez PA, de Launoit Y. Differential expression patterns of the PEA3 group transcription factors through murine embryonic development. Oncogene 1997; 15: 937-952 [PMID: 9285689 DOI: 10.1038/sj.onc.1201261]
7. Chotteau-Lelievre A, Montesano R, Soriano J, Soulie P, Desbiens X, de Launoit Y. PEA3 transcription factors are expressed in tissues undergoing branching morphogenesis and promote formation of duct-like structures by mammary epithelial cells in vitro. Dev Biol 2003; 259: 241-257 [PMID: 12871699]
8. Zhang Z, Verheyden JM, Hassell JA, Sun X. FGF-regulated Etv genes are essential for repressing Shh expression in mouse limb buds. Dev Cell 2009; 16: 607-613 [PMID: 19386269 DOI: 10.1016/j.devcel.2009.02.008]
9. Benz CC, O'Hagan RC, Richter B, Scott GK, Chang CH, Xiong X, Chew K, Ljung BM, Edgerton S, Thor A, Hassell JA. HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. Oncogene 1997; 15: 1513-1525 [PMID: 9380403 DOI: 10.1038/sj.onc.1201331]
10. Fleming FJ, Myers E, Kelly G, Crotty TB, McDermott EW, O'Higgins NJ, Hill AD, Young LS. Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1. J Clin Pathol 2004; 57: 1069-1074 [PMID: 15452162 DOI: 10.1136/jcp.2004.016733]
11. Myers E, Hill AD, Kelly G, McDermott EW, O'Higgins NJ, Young LS. A positive role for PEA3 in HER2-mediated breast tumour progression. Br J Cancer 2006; 95: 1404-1409 [PMID: 17060941]
12. Keld R, Guo B, Downey P, Cummins R, Gulmann C, Ang YS, Sharrocks AD. PEA3/ETV4-related transcription factors coupled with active ERK signalling are associated with poor prognosis in gastric adenocarcinoma. Br J Cancer 2011; 105: 124-130 [PMID: 21673681 DOI: 10.1038/bjc.2011.187]
13. Keld R, Guo B, Downey P, Gulmann C, Ang YS, Sharrocks AD. The ERK MAP kinase-PEA3/ETV4-MMP-1 axis is operative in oesophageal adenocarcinoma. Mol Cancer 2010; 9: 313 [PMID: 21143918 DOI: 10.1186/1476-4598-9-313]
14. Sloan KA, Marquez HA, Li J, Cao Y, Hinds A, O'Hara CJ, Kathuria S, Ramirez MI, Williams MC, Kathuria H. Increased PEA3/E1AF and decreased Net/Elk-3, both ETS proteins, characterize human NSCLC progression and regulate caveolin-1 transcription in Calu-1 and NCI-H23 NSCLC cell lines. Carcinogenesis 2009; 30: 1433-1442 [PMID: 19483189 DOI: 10.1093/carcin/bgp129]
15. Horiuchi S, Yamamoto H, Min Y, Adachi Y, Itoh F, Imai K. Association of ets-related transcriptional factor E1AF expression with tumour progression and overexpression of MMP-1 and matrilysin in human colorectal cancer. J Pathol 2003; 200: 568-576 [PMID: 12898592 DOI: 10.1002/path.1387]
16. Asting AG, Carén H, Andersson M, Lönnroth C, Lagerstedt K, Lundholm K. COX-2 gene expression in colon cancer tissue related to regulating factors and promoter methylation status. BMC Cancer 2011; 11: 238 [PMID: 21668942 DOI: 10.1186/1471-2407-11-238]
17. Boedefeld WM, Soong R, Weiss H, Diasio RB, Urist MM, Bland KI, Heslin MJ. E1A-F is overexpressed early in human colorectal neoplasia and associated with cyclooxygenase-2 and matrix metalloproteinase-7. Mol Carcinog 2005; 43: 13-17 [PMID: 15800927 DOI: 10.1002/mc.20093]
18. Liu Y, Borchert GL, Phang JM. Polyoma enhancer activator 3, an ets transcription factor, mediates the induction of cyclooxygenase-2 by nitric oxide in colorectal cancer cells. J Biol Chem 2004; 279: 18694-18700 [PMID: 14976201 DOI: 10.1074/jbc.M308136200]
19. Lynch CC, Crawford HC, Matrisian LM, McDonnell S. Epidermal growth factor upregulates matrix metalloproteinase-7 expression through activation of PEA3 transcription factors. Int J Oncol 2004; 24: 1565-1572 [PMID: 15138601]
20. Yuen HF, Chan YK, Grills C, McCrudden CM, Gunasekharan V, Shi Z, Wong AS, Lappin TR, Chan KW, Fennell DA, Khoo US, Johnston PG, El-Tanani M. Polyomavirus enhancer activator 3 protein promotes breast cancer metastatic progression through Snail-induced epithelial-mesenchymal transition. J Pathol 2011; 224: 78-89 [PMID: 21404275 DOI: 10.1002/path.2859]
21. de Launoit Y, Chotteau-Lelievre A, Beaudoin C, Coutte L, Netzer S, Brenner C, Huvent I, Baert JL. The PEA3 group of ETS-related transcription factors. Role in breast cancer metastasis. Adv Exp Med Biol 2000; 480: 107-116 [PMID: 10959416 DOI: 10.1007/0-306-46832-8-13]
22. Hakuma N, Kinoshita I, Shimizu Y, Yamazaki K, Yoshida K, Nishimura M, Dosaka-Akita H. E1AF/PEA3 activates the Rho/Rho-associated kinase pathway to increase the malignancy potential of non-small-cell lung cancer cells. Cancer Res 2005; 65: 10776-10782 [PMID: 16322223 DOI: 10.1158/0008-5472.CAN-05-0060]
23. Aytes A, Mitrofanova A, Kinkade CW, Lefebvre C, Lei M, Phelan V, LeKaye HC, Koutcher JA, Cardiff RD, Califano A, Shen MM, Abate-Shen C. ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer. Proc Natl Acad Sci USA 2013; 110: E3506-E3515 [PMID: 23918374 DOI: 10.1073/pnas.1303558110]
24. Habelhah H, Okada F, Kobayashi M, Nakai K, Choi S, Hamada J, Moriuchi T, Kaya M, Yoshida K, Fujinaga K, Hosokawa M. Increased E1AF expression in mouse fibrosarcoma promotes metastasis through induction of MT1-MMP expression. Oncogene 1999; 18: 1771-1776 [PMID: 10208438 DOI: 10.1038/sj.onc.1202465]
25. Nosho K, Yoshida M, Yamamoto H, Taniguchi H, Adachi Y, Mikami M, Hinoda Y, Imai K. Association of Ets-related transcriptional factor E1AF expression with overexpression of matrix metalloproteinases, COX-2 and iNOS in the early stage of colorectal carcinogenesis. Carcinogenesis 2005; 26: 892-899 [PMID: 15695237 DOI: 10.1093/carcin/bgi029]
26. Liu SK, Bham SA, Fokas E, Beech J, Im J, Cho S, Harris AL, Muschel RJ. Delta-like ligand 4-notch blockade and tumor radiation response. J Natl Cancer Inst 2011; 103: 1778-1798 [PMID: 22010178 DOI: 10.1093/jnci/djr419]
27. Kassis J, Lauffenburger DA, Turner T, Wells A. Tumor invasion as dysregulated cell motility. Semin Cancer Biol 2001; 11: 105-117 [PMID: 11322830 DOI: 10.1006/scbi.2000.0362]
28. Wells A. Tumor invasion: role of growth factor-induced cell motility. Adv Cancer Res 2000; 78: 31-101 [PMID: 10547668]
29. Kleinman HK, Jacob K. Invasion assays. Curr Protoc Cell Biol 2001; Chapter 12: Unit 12.2 [PMID: 18228316 DOI: 10.1002/0471143030.cb1202s00]
30. Taddei ML, Giannoni E, Fiaschi T, Chiarugi P. Anoikis: an emerging hallmark in health and diseases. J Pathol 2012; 226: 380-393 [PMID: 21953325 DOI: 10.1002/path.3000]
31. Bresalier RS, Raper SE, Hujanen ES, Kim YS. A new animal model for human colon cancer metastasis. Int J Cancer 1987; 39: 625-630 [PMID: 3032811]
32. Ishizu K, Sunose N, Yamazaki K, Tsuruo T, Sadahiro S, Makuuchi H, Yamori T. Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells. Biol Pharm Bull 2007; 30: 1779-1783 [PMID: 17827739]
33. Zucker S, Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 2004; 23: 101-117 [PMID: 15000152]
34. Bhangu A, Wood G, Mirnezami A, Darzi A, Tekkis P, Goldin R. Epithelial mesenchymal transition in colorectal cancer: Seminal role in promoting disease progression and resistance to neoadjuvant therapy. Surg Oncol 2012; 21: 316-323 [PMID: 22981546 DOI: 10.1016/j.suronc.2012.08.003]
35. Martinez C, Churchman M, Freeman T, Ilyas M. Osteopontin provides early proliferative drive and may be dependent upon aberrant c-myc signalling in murine intestinal tumours. Exp Mol Pathol 2010; 88: 272-277 [PMID: 20053348 DOI: 10.1016/j.yexmp.2009.12.008]
36. Mole DJ, O'Neill C, Hamilton P, Olabi B, Robinson V, Williams L, Diamond T, El-Tanani M, Campbell FC. Expression of osteopontin coregulators in primary colorectal cancer and associated liver metastases. Br J Cancer 2011; 104: 1007-1012 [PMID: 21343932 DOI: 10.1038/bjc.2011.33]
37. Bièche I, Tozlu S, Girault I, Onody P, Driouch K, Vidaud M, Lidereau R. Expression of PEA3/E1AF/ETV4, an Etsrelated transcription factor, in breast tumors: positive links to MMP2, NRG1 and CGB expression. Carcinogenesis 2004; 25: 405-411 [PMID: 14633660 DOI: 10.1093/carcin/bgh024]
38. Gum R, Lengyel E, Juarez J, Chen JH, Sato H, Seiki M, Boyd D. Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J Biol Chem 1996; 271: 10672-10680 [PMID: 8631874]
39. Jia W, Gao XJ, Zhang ZD, Yang ZX, Zhang G. S100A4 silencing suppresses proliferation, angiogenesis and invasion of thyroid cancer cells through downregulation of MMP-9 and VEGF. Eur Rev Med Pharmacol Sci 2013; 17: 1495-1508 [PMID: 23771538]
40. Zhang G, Li M, Jin J, Bai Y, Yang C. Knockdown of S100A4 decreases tumorigenesis and metastasis in osteosarcoma cells by repression of matrix metalloproteinase-9. Asian Pac J Cancer Prev 2011; 12: 2075-2080 [PMID: 22292654]
41. Wang L, Wang X, Liang Y, Diao X, Chen Q. S100A4 promotes invasion and angiogenesis in breast cancer MDA-MB-231 cells by upregulating matrix metalloproteinase-13. Acta Biochim Pol 2012; 59: 593-598 [PMID: 23162804]
42. Boye K, Maelandsmo GM. S100A4 and metastasis: a small actor playing many roles. Am J Pathol 2010; 176: 528-535 [PMID: 20019188 DOI: 10.2353/ajpath.2010.090526]
43. Burnett JC, Rossi JJ, Tiemann K. Current progress of siR-NA/shRNA therapeutics in clinical trials. Biotechnol J 2011; 6: 1130-1146 [PMID: 21744502 DOI: 10.1002/biot.201100054]